OOIR: Observatory of International Research

Papers

(The median citation count of Current Opinion in Lipidology is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
Alveolar macrophages: guardians of the alveolar lipid galaxy	60
Triglyceride-rich lipoproteins, remnant-cholesterol, and atherosclerotic cardiovascular disease	59
Ups and downs in PCSK9 inhibition in the cardiovascular arena: a review	58
Editorial introductions	57
Familial hypercholesterolemia-Plus: is the metabolic syndrome changing the clinical picture of familial hypercholesterolemia?	44
Angiopoietin-like protein 8: a multifaceted protein instrumental in regulating triglyceride metabolism	43
Genetic variation in apolipoprotein A-V in hypertriglyceridemia	36
ANGPTL4: a new mode in the regulation of intravascular lipolysis	34
Sphingomyelins and ceramides: possible biomarkers for dementia?	32
Implementation science and genetic testing for familial hypercholesterolemia	31
Universal screening for familial hypercholesterolaemia: how can we maximise benefits and minimise potential harm for children and their families?	30
The lipid-heart hypothesis from the Seven Countries Study of Cardiovascular Diseases	30
Exosomes and lipid metabolism in metabolic and cardiovascular disorders	28
Familial hypercholesterolemia: The nexus of endothelial dysfunction and lipoprotein metabolism in COVID-19	22
Familial hypercholesterolemia in children and the importance of early treatment	19
Oxidized LDL receptors: a recent update	18
Lipid metabolism during pregnancy: consequences for mother and child	17
Lipoprotein(a) and peripheral artery disease: contemporary evidence and therapeutic advances	17
Editorial introductions	16
Nonalcoholic fatty liver disease: an update	16
Splice correction therapies for familial hypercholesterolemic patients with low-density lipoprotein receptor mutations	15
Genetic determinants of pancreatitis risk in hypertriglyceridemia	15
A new SPRING in lipid metabolism	14
Nutrition and its impact on cardiovascular disease	14
From clinical development to real-world outcomes with inclisiran	14

Familial hypercholesterolemia in pregnancy	14
The complex pro-atherosclerotic role of lipoprotein(a): a multiplicity of cellular targets	14
The current state of apolipoprotein E in dyslipidemia	14
The need for national and international registries of patients with elevated lipoprotein(a)	14
APOE and familial hypercholesterolemia	14
High-density lipoprotein functionality, cardiovascular health, and patterns of alcohol consumption: new insights and future perspectives	13
ANGPTL3 and ApoC-III inhibitors for treating hypertriglyceridemia in context: horses for courses?	13
Can small dense LDL cholesterol be estimated from the lipid profile?	12
The emerging role of fat-inducing transcript 2 in endoplasmic reticulum proteostasis and lipoprotein biogenesis	12
Inclisiran: present and future perspectives of a new effective LDL cholesterol-lowering agent	12
Are the lipid-lowering effects of incretin-based therapies relevant for cardiovascular benefit?	12
The intracellular chylomicron highway: novel insights into chylomicron biosynthesis, trafficking, and secretion	12
Newborn screening for lipid disorders	11
Editorial introductions	11
Recent dynamic studies of the metabolism of atherogenic lipoproteins: elucidating the mode of action of new therapies	11
In the wake of the Scandinavian Simvastatin Survival Study trial	10
Cardiomyocytes, sphingolipids and cardio myotoxicity	10
Distinct roles of size-defined HDL subpopulations in cardiovascular disease	10
Beyond cholesterol: linking the conformation of apolipoprotein B to atherogenesis	10
Clinical associations between exercise and lipoproteins	9
Pregnancy, cardiovascular health, and microchimerism	9
Circulating protein and lipid markers of early sepsis diagnosis and prognosis: a scoping review	9
Altered cardiovascular risk pattern of LDL cholesterol in older adults	9
The expanding role of lyso-phosphatidylcholine acyltransferase-3 (LPCAT3), a phospholipid remodeling enzyme, in health and disease	9
Strategies for management of patients with elevated lipoprotein(a)	9
Genetic testing for familial hypercholesterolemia	8
Preprint servers in lipidology: current status and future role	8
Association of dietary patterns and components with atherosclerosis risk biomarkers in familial hypercholesterolemia	8
Sphingosine-1-phosphate: metabolism, transport, atheroprotection and effect of statin treatment	7
Genotype–phenotype correlation in a large cohort of pediatric patients with heterozygous and homozygous familial hypercholesterolemia	7
Prevention of cardiometabolic diseases through dietary modifications	7
The pathophysiology of excess plasma-free cholesterol	7
Navigating variants of uncertain significance in genetic dyslipidemia: how to assess and counsel patients	6
Clonal hematopoiesis of indeterminate potential and the evolutionary lottery in chromosome 2: does that make human atherosclerosis special?	6
The feedback cycles between glucose, amino acids and lipids and alpha cell secretion and their role in metabolic fatty liver disease	6
Dietary fat, telomere length and cognitive function: unravelling the complex relations	6
A contemporary snapshot of familial hypercholesterolemia registries	5
Assessment of cardiovascular disease risk: a 2023 update	5
Atherogenic low-density lipoprotein and cardiovascular risk	5
How should low-density lipoprotein cholesterol be calculated in 2022?	5
Diagnosis of remnant hyperlipidaemia	5
Editorial introductions	5
Recent lipoprotein(a) trials	5
Therapeutic application of genome editing in dyslipidemia	5
Predictors of cardiovascular risk in familial hypercholesterolemia	5
Proprotein convertase subtilisin/kexin type 9-inhibition across different patient populations	5
Lipidomics in gestational diabetes mellitus	5
Translating guidelines into practice via implementation science: an update in lipidology	5
Dietary factors and brain health	5
Resolution of apolipoprotein A1 and A2 proteoforms: their cardiometabolic correlates and implications for future research	5

Remnant cholesterol as a new lipid-lowering target to reduce cardiovascular events	5
Orticumab: the potential to harness oxidized LDL to reduce coronary inflammation with plaque-targeted therapy	4
Consensus and guidelines on lipoprotein(a) – seeing the forest through the trees	4
Bempedoic acid for nonalcoholic fatty liver disease: evidence and mechanisms of action	4
Novel therapeutic opportunities for familial lecithin:cholesterol acyltransferase deficiency: promises and challenges	4
Editorial introduction	4
Regulation of cardiovascular calcification by lipids and lipoproteins	4
Are Lipoprotein(a) levels decreased in insulin resistance and type 2 diabetes?	4
Inflammation in atherosclerosis: a Big Idea that has underperformed so far	4
Triglyceride-rich lipoprotein cholesterol and cardiovascular risk	4
Understanding the ins and outs of lipoprotein (a) metabolism	4
Basic and translational evidence supporting the role of TM6SF2 in VLDL metabolism	4
Genetics of remnant cholesterol	4
Established and potential cardiovascular risk factors in metabolic syndrome: Effect of bariatric surgery	4
Cholesteryl ester transfer protein inhibition: a pathway to reducing risk of morbidity and promoting longevity	3
Fatty acid metabolism in cancer cells – the power of plasticity	3
Editorial introduction	3
Bempedoic acid: new evidence and recommendations on use	3
Lipids and brain inflammation in APOE4-associated dementia	3
PCSK9-directed therapies: an update	3
Complex actions of sodium glucose transporter-2 inhibitors on lipids, calcific atherosclerosis, and bone density	3
Macrophage SR-B1 in atherosclerotic cardiovascular disease	3
Circulating cell-free DNA and its association with cardiovascular disease: what we know and future perspectives	3
Lipoprotein (a) in familial hypercholesterolaemia	2
Editorial introductions	2
Polygenic contribution for familial hypercholesterolemia (FH)	2
Ketogenic therapies in mild cognitive impairment and dementia	2
Lipidome and inflammation interplay: the role of diet in this relationship	2
Proprotein convertase subtilisin/kexin type 9 inhibition after acute coronary syndrome or prior myocardial infarction	2
Editorial introductions	2
Cycling of metabolic states and metabolites as drivers of atherosclerosis	2
Brain lipid metabolism: the emerging role of lipid droplets in glial cells	2
Familial combined hyperlipidemia is a polygenic trait	2
Angiopoietin-like 3 inhibition and the liver: less is more?	2
G protein-coupled receptor 146: new insights from genetics and model systems	2
Dyslipidemia and aortic valve disease	2
Updates on genetics and molecular biology	2
Proprotein convertase subtilisin/kexin type 9 as a drug target for abdominal aortic aneurysm	2
SPRINGing off the lock: the role of SPRING in S1P activity and SREBP-regulated lipid metabolism	2